Effects of Acute Intermittent Hypoxia on Neuroplasticity in MS
NCT06390930
Summary
This study seeks to explore changes in the neural pathways and arm function following a breathing intervention in the multiple sclerosis (MS) population. The breathing intervention, known as Acute Intermittent Hypoxia (AIH), involves breathing brief bouts of low levels of oxygen. Research has found AIH to be a safe and effective intervention resulting in increased ankle strength in people with MS. Here, the study examines arm and hand function before and after AIH. In order to better understand the brain and spinal cord response to AIH, the investigators will measure muscle response, and signals sent from the brain to the arm muscles before and after AIH.
Eligibility
Inclusion Criteria: * Diagnosis of relapsing-remitting MS according to the McDonald criteria, over 5 years ago * Relapse free for at least 6 months * Expanded Disability Status Scale (EDSS) ≤7 * Index finger abduction strength \<5 according to Medical Research Council Scale, or 9-Hole Peg Test score \>20 seconds in at least one hand * Stable disease modifying therapies for at least 6 months * Individuals taking dalfampridine will be eligible if taking the same daily dose for at least 2 months prior to screening Exclusion Criteria: * Another diagnosis (e.g., peripheral neuropathies or orthopedic) affecting upper limb function * Mini-Mental State Examination (MMSE) score \<24 * Modified Ashworth Scale score \>3 on elbow joint * Uncontrolled hypertension or hypotension (outside 140/90 and 85/55 mmHg) * History of epilepsy, chronic obstructive pulmonary disease, or sleep apnea * Unstable medical conditions, ongoing upper limb therapy, or musculoskeletal pain * Pregnancy as confirmed by urine test
Conditions3
Locations1 site
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
NCT06390930